In Part 2 of 2 videos about squamous lung cancer, Dr.

Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.

For those who wish to access the PDF, it's here: Thomas John, MD Top Four Lung Cancer Highlights 2014

Agree? Disagree? What are you looking forward to in 2015?

There were many advances in lung cancer targeted treatments in 2014. The one that most excites Dr. Geoffrey Oxnard from Dana-Farber Cancer Institute is the use of liquid biopsies.

[powerpress]

Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.

[powerpress]

Dr. Lecia Sequist provides her thoughts on how molecular oncology can soon begin affecting treatment plans for a broader range of patients with lung cancer, including those with squamous NSCLC and other lung cancer histologies.

[powerpress]

Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly available to oncologists seeing patients in the community setting.

[powerpress]

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

[powerpress]